A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...

Shares of Gilead Sciences Inc. GILD advanced 2.46% to $111.11 Thursday, on what proved to be an all-around positive trading ...

At Thursday night memorial, Mt. Gilead pastor Doug Bryan reads message about slain Morrow County deputy Daniel Weston Sherrer ...

Spoiler alert! Here's how Hulu's "The Handmaid's Tale" ends after six long seasons of June (Elisabeth Moss) in Gilead.

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

This was the stock's second consecutive day of gains.

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Gilead Sciences says it still plans to supply its ...

Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...